Idex Corp. growth rate to resume over next few quarters, says Argus

Argus keeps a Buy rating and $255 price target on Idex Corp while noting that the company is well positioned for the future. Shares have underperformed the market over the past three months, losing 1% while the S&P 500 has risen 4%, but the firm is anticipating an improvement in the company’s earnings growth rate over the next few quarters as slower order growth in the Health & Science segment was due to satisfactory inventory levels, the analyst tells investors in a research note.